DynaGen
This article was originally published in The Gray Sheet
Executive Summary
Nets approximately $5.8 mil. from offering of 1.6 mil. units at $4.50 per unit, each consisting of four shares of common and two warrants. Each warrant, which is separately transferable immediately upon issuance, enables the holder to purchase one share of common for $1.20 for up to five years. RAS Securities Corp. and Thomas James Associates were the underwriters for the deal
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.